Crabtree Naomi E, Epstein Kira L
Department of Large Animal Medicine, University of Georgia College of Veterinary Medicine, Athens, GA, United States.
Front Vet Sci. 2021 Mar 29;8:648774. doi: 10.3389/fvets.2021.648774. eCollection 2021.
Despite the frequent inclusion of fluid therapy in the treatment of many conditions in horses, there are limited studies available to provide evidenced-based, species-specific recommendations. Thus, equine fluid therapy is based on the application of physiology and extrapolation from evidence in other veterinary species and human medicine. The physiologic principles that underly the use of fluids in medicine are, at first glance, straightforward and simple to understand. However, in the past 20 years, multiple studies in human medicine have shown that creating recommendations based on theory in combination with experimental and/or small clinical studies does not consistently result in best practice. As a result, there are ongoing controversies in human medicine over fluid types, volumes, and routes of administration. For example, the use of 0.9% NaCl as the replacement fluid of choice is being questioned, and the theoretical benefits of colloids have not translated to clinical cases and negative effects are greater than predicted. In this review, the current body of equine research in fluid therapy will be reviewed, connections to the controversies in human medicine and other veterinary species will be explored and, where appropriate, recommendations for fluid therapy in the adult horse will be made based on the available evidence. This review is focused on the decisions surrounding developing a fluid plan involving crystalloids, synthetic colloids, and plasma.
尽管在马的许多疾病治疗中经常采用液体疗法,但可用于提供基于证据的、针对该物种的建议的研究有限。因此,马的液体疗法是基于生理学的应用以及从其他兽医物种和人类医学的证据中推断而来。乍一看,医学中使用液体的生理原理简单易懂。然而,在过去20年里,人类医学的多项研究表明,基于理论结合实验和/或小型临床研究制定建议并不能始终带来最佳实践。因此,人类医学在液体类型、用量和给药途径方面存在持续的争议。例如,使用0.9%氯化钠作为首选替代液体受到质疑,胶体的理论益处并未转化为临床病例,且负面影响大于预期。在本综述中,将回顾马液体疗法的现有研究主体,探讨与人类医学和其他兽医物种争议的联系,并在适当情况下根据现有证据对成年马的液体疗法提出建议。本综述重点关注围绕制定涉及晶体液、合成胶体和血浆的液体治疗方案的决策。